Monte Rosa dan BioAge anjlok pasca kegagalan Novo Nordisk (GLUE:NASDAQ)

· seekingalpha.com

Kegagalan uji klinis obat jantung Novo Nordisk (NVO) memicu keraguan terhadap obat anti-inflamasi yang dikembangkan oleh Monte Rosa (GLUE) dan BioAge Labs (BIOA). Baca selengkapnya di sini.

Shares of Monte Rosa Therapeutics (GLUE) and BioAge Labs (BIOA) fell sharply on Friday after a late-stage trial setback for Novo Nordisk (NVO) called into quest...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI